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Background: The incidence of papillary thyroid cancer (PTC) is markedly higher in women than men during the
reproductive years. In vitro studies have suggested that estrogen may play an important role in the development
and progression of PTC through estrogen receptors (ERs). This study aimed to investigate the expression patterns
of the two main ER subtypes, α and β1 (wild-type ERβ), in PTC tissue and their clinical significance.
Methods: Immunohistochemical staining of thyroid tissue sections was performed to detect ER expression in female
patients with PTC (n = 89) and nodular thyroid goiter (NTG; n = 30) using the Elivision™ plus two-step system. The
relationships between ER subtype expression and clinicopathological/biological factors were further analyzed.
Results: The positive percentage and expression levels of ERα were significantly higher in female PTC patients of
reproductive age (18–45 years old; n = 50) than age-matched female NTG patients (n = 30), while ERβ1 exhibited
the opposite pattern. There was no difference in ERα or ERβ1 expression between female PTC patients of reproductive
age and those of advanced reproductive age (>45 years old; n = 39). In the female PTC patients of reproductive age,
ERα expression level was positively correlated with that of Ki-67, while ERβ1 was negatively correlated with mutant P53.
Furthermore, more patients with exclusively nuclear ERα expression had extrathyroidal extension (ETE) as compared
with those with extranuclear ERα localization. VEGF expression was significantly decreased in female PTC patients of
reproductive age with only nuclear ERβ1 expression when compared with those with extranuclear ERβ1 localization.
In PTC patients of advanced reproductive age, neither ERα nor ERβ1 expression showed any correlation with that of
Ki-67, mutant P53, VEGF, tumor size, TNM stage, ETE, or lymph node metastases.
Conclusions: The differential expression patterns of the two ER subtypes between PTC and NTG indicate that ERα
may be a useful immunohistochemical marker for differential diagnosis of PTC. The associations of ER subtype
expression with Ki-67, mutant P53, VEGF expression and ETE in female PTC patients of reproductive age suggest
that estrogen-activated ERα may mediate stimulatory effects on PTC growth and progression whereas ERβ1 has
some inhibitory actions.
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Papillary thyroid cancer (PTC) is the most common
endocrine malignancy, and its incidence has rapidly
increased in recent years [1]. PTC is usually indolent
and curable after standard thyroidectomy in combination
with TSH-suppressive levothyroxine therapy and radioio-
dine treatment, but can spread early to local lymph nodes.
In addition, disease persistence and/or recurrence are
common and associated with increased mortality [2].
According to the SEER 9 database of the National Cancer
Institute in the USA, the female-to-male incidence ratio of
PTC declined from more than five at ages 20–24 to 3.4 at
ages 35–44, approaching one at ages 80+, and was greatest
during reproductive age [3]. The predominance of PTC in
females was observed in all geographical areas and ethnic
groups [1,4]. Furthermore, Brindel et al. reported that the
risk of thyroid cancer was significantly increased after
natural or artificial menopause as compared with that
at premenopausal status, and also with the number of
births [5]. It has been found that estrogen can regulate
the transcription of many cell proliferation-related
genes [6-8]. There is also much evidence that estrogen
has direct actions in thyroid cell lines originating from
normal thyroid gland tissue and thyroid carcinoma by
ER-dependent mechanisms, such as enhancement of
proliferation, modulation of sodium-iodide symporter
and thyroglobulin gene expression, and upregulation of
matrix metalloproteinase 9 production [8-10]. The above
findings indicate that the growth and progression of thy-
roid malignancies are influenced by female sex hormones,
particularly estrogen [1]. Estrogen signaling is classically
mediated upon the binding of two soluble intracellular
receptors, ERα and ERβ [8]; the splice variant ERβ1 is
wild-type ERβ. Several studies have investigated the
expression of ER subtypes in thyroid cancers without
consistent results as yet [8,11-13]. This may be owed to
the existence of confounding factors in the subjects who
were included in those analyses, such as age, gender and
cancer types. Moreover, the precise contributions of the
two ER subtypes have not been well understood [1,4]. This
study was therefore performed to systemically investigate
the expression patterns of ERα and ERβ1 in female PTC
patients stratified by age, and to further analyze their
relationships with important clinicopathological factors
(e.g., tumor size) and biological markers (e.g., Ki-67).
Methods
Patients and tissue specimens
Thyroid specimens were obtained from 89 female Chinese
patients with PTC, including 50 of reproductive age
(18–45 years old), 39 of advanced reproductive age
(>45 years old), and 30 of reproductive age with nodular
thyroid goiter (NTG). All patients had a clinical duration
of less than 3 years, and were admitted to our hospital forstandard thyroidectomy from 2007 to 2010; those who
underwent secondary surgery for PTC were excluded.
Diagnoses were confirmed through histopathological
examination by pathologists at our hospital. None of the
PTC patients had a history of familial thyroid cancer or
neck external irradiation. Patients with concomitant PTC
and NTG as well as those only with papillary thyroid
microcarcinoma were excluded from this study. All these
criteria contributed to fewer confounding factors and
greater homogeneity among the subjects. Clinicopatholog-
ical data, such as tumor size, presence of extrathyroidal
extension (ETE) and lymph node metastases (LNM), were
retrieved from the relevant medical records. ETE was
defined as invasion of adjacent organs or skeletal muscle
outside the isthmus [14]. TNM stage was assessed accord-
ing to the 7th edition of the tumor, node and metastasis
system classification proposed by the American Joint
Committee on cancer. This study was approved by the
Institutional Review Board of the First Affiliated Hospital
of China Medical University, and was in compliance
with the Helsinki Declaration (AF-SOP-07-1.0-01). All
patients gave written informed consent for participation in
the study.
Immunohistochemistry
Immunohistochemical (IHC) staining for ERα and ERβ1
was performed on 4-μm-thick formalin-fixed and paraffin-
embedded sections of surgical specimens from PTC and
NTG patients using the Elivision™ plus two-step system
(Maxim Biotech Inc, Fuzhou, China), which has been
proved superior to biotin-based SP and ABC detection
systems due to large amounts of endogenous biotin
present in thyroid [15,16]. Ki-67, mutant P53 and vascular
epithelial growth factor (VEGF) are important growth-
related biological markers for cancer. These proteins were
examined in PTC specimens by IHC staining as described
above. Briefly, the tissue sections were deparaffinized,
rehydrated and subjected to microwave antigen retrieval
in 10 mM citrate buffer (pH 6.0) for 20–25 min. Endogen-
ous peroxidase was then blocked with 3% H2O2 for
10 min. After washing three times in phosphate buffered
saline (PBS), the sections were incubated with a primary
antibody against ERα (Clone 1D5, Dako; 1:200), ERβ1
(Clone PPG5/10, Serotec; 1:20), Ki-67 (Clone SP6, Abcam;
1:100), mutant P53 (Clone N235K N239Y, Bioss; 1:350) or
VEGF (Clone EP1176Y, Abcam; 1:100) at 4°C overnight.
Then, staining was performed according to the manufac-
turer’s instructions. Color reactions were performed with
3,3′-diamino-benzidine (DAB; Maxim Biotech Inc). The
sections were then counterstained with hematoxylin,
washed, dehydrated in alcohol, cleared in xylene, and
mounted with coverslips. Appropriate positive and nega-
tive controls were used in each batch of staining experi-
ments. Tissue sections from human breast cancer were
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control sections were incubated with normal mouse or
rabbit IgG instead of a specific primary antibody.
Review and scoring of stained tissue sections
Immunostained tissue sections were reviewed, scored
and interpreted using the Allred score [17]. In brief, each
section was carefully evaluated using light microscopy.
A proportion staining score (PS) was assigned, which
represented the estimated proportion of positive-staining
cells as follows: 0, no staining; 1, <1⁄100; 2, 1⁄100 to 1⁄10;
3,1⁄10 to 1⁄3; 4, 1⁄3 to 2⁄3; and 5, >2⁄3. An intensity score
(IS) was also assigned to represent the average intensity of
positive cells in each section as follows: 0, no staining; 1,
weak; 2, intermediate; and 3, strong. Finally, a total score
(TS) was calculated from the sum of PS and IS (range 0,
2–8) to reflect the expression level. “Positive” staining was
then defined as the TS ≥3. The sections were coded
and analyzed separately by two independent investiga-
tors (Y.H. and W.D.), who were blinded to the other
data regarding the sections. If discrepancies occurred, a
third investigator (J.L.) evaluated the tissue sections to
achieve a consistent result.
Statistical analysis
Descriptive statistics were performed according to the
distribution of variables. The Mann–Whitney U test was
used for comparisons of quantitative variables between
groups. The Chi-square test was used for comparisons
of qualitative variables between groups. Relationships
between ER subtype expression and biological markers
were assessed using Spearman’s correlation analysis. All
statistical analyses were performed with SPSS software
(version 17.0, SPSS Inc., Chicago, IL, USA). Differences
were considered statistically significant if P < 0.05.
Results
Expression patterns of ERα and ERβ1 in female PTC patients
Both the positive percentage and total score of ERα
expression were significantly increased in female PTC
patients of reproductive age as compared with that of
age- and gender-matched NTG patients (Figure 1,
Table 1). In addition, the subcellular localization of ERα
was markedly different between PTC (26.7% with extranu-
clear expression) and NTG (no extranuclear expression).
Notably, the expression level (i.e., total score) of ERβ1
was significantly lower in PTC lesions than NTG tissue
(Figure 1, Table 1). Extranuclear ERβ1 expression was
markedly more frequent in female PTC patients (85.4%)
when compared with that of the NTG control group
(17.9%) at reproductive age.
The percentage of female PTC patients with extranuclear
ERα expression was significantly lower at reproductive age
(26.7%) than that at advanced reproductive age (61.1%).There was no significant difference in the positive percent-
age or expression level of either ER subtype between
female PTC patients of reproductive age and those of
advanced reproductive age (Table 2).
Relationships between ERα/ERβ1 expression and
clinicopathological/biological factors in female PTC patients
In female PTC patients of reproductive age or advanced
reproductive age, there were no significant differences
in the positive percentages or expression levels of the
two ER subtypes when comparing tumor size (≤20 mm
vs >20 mm), LNM (positive vs negative), ETE (positive vs
negative) or TNM stage (I/II vs III/IV) (data not shown).
The expression of Ki-67, mutant P53 and VEGF in PTC
lesions were examined as shown in Figure 2. Ki-67 is
expressed in the nuclei of some PTC cells, and has been
used as a marker for cell proliferation and prognosis in
thyroid tumors, especially PTC [18]. Mutant P53 detection
by IHC exhibited combined nuclear and cytoplasmic
staining in PTC lesions, similar to the expression pattern
reported in colorectal cancer and melanoma [19,20].
Mutant P53 has been recognized as a prognostic indicator
for survival in PTC patients with a growth-promoting
effect [21-23]. Similarly, cytoplasmic staining of VEGF
was found in PTC tissues; VEGF is an important regulator
of pathological neovascularization, and is especially in-
volved in tumor growth and metastasis [24]. The total
score of ERα expression was positively correlated with that
of Ki-67 (r = 0.332, P = 0.028), while ERβ1 expression had
a negative correlation with that of mutant P53 protein
(r = −0.313, P = 0.039) in female PTC patients of repro-
ductive age. The expression of neither ERα nor ERβ1
was significantly correlated with that of Ki-67, mutant
P53 or VEGF in those of advanced reproductive age.
Relationships between subcellular localization of ERα/
ERβ1 and clinicopathological/biological factors in female
PTC patients
As described above, ER subtypes were found to exhibit
three types of expression patterns in PTC lesions—
combined nuclear and cytoplasmic, exclusively nuclear or
cytoplasmic localization. Among the female PTC patients
of reproductive age, ETE occurred more frequently in
those with exclusively nuclear ERα expression than
with extranuclear localization of ERα (i.e., exclusively
cytoplasmic or combined cytoplasmic and nuclear expres-
sion; Table 3). In addition, both the positive percentage
and total score of VEGF expression were significantly
decreased in samples with exclusively nuclear ERβ1
expression as compared with those demonstrating extra-
nuclear localization of ERβ1 (Table 4). Among the female
PTC patients of advanced reproductive age, no difference
was found in the subcellular distribution of ERα or ERβ1
between tumors of different sizes, LNM, ETE or TNM
Figure 1 Immunohistochemical staining of ERα and ERβ1 in PTC lesions and NTG tissue (400×). ERα and ERβ1 expression was analyzed by
immunohistochemical staining of formalin-fixed and paraffin-embedded thyroid tissue sections from patients with papillary thyroid cancer (PTC) and
those with nodular thyroid goiter (NTG) using specific antibodies and the Elivision™ plus two-step system. (A) NTG tissue with negative ERα staining;
(B) NTG tissue with positive nuclear ERα staining (total score 6); (C) PTC tissue with negative ERα staining; (D) PTC tissue with positive nuclear ERα
staining (total score 8); (E) PTC tissue with positive nuclear and cytoplasmic ERα staining (total score 7); (F) NTG tissue with negative ERβ1
staining; (G) NTG tissue with positive nuclear ERβ1 staining (total score 8); (H) NTG tissue with positive nuclear and cytoplasmic ERβ1 staining
(total score 7); (I) PTC tissue with negative ERβ1 staining; (J) PTC tissue with positive nuclear ER β1 staining (total score 6); (K) PTC tissue with
positive nuclear and cytoplasmic ERβ1 staining (total score 7); (L) PTC tissue with positive cytoplasmic ERβ1 staining (total score 5).
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expression of Ki-67, mutant P53 or VEGF between the
samples with exclusively nuclear ER subtype expression
and those with its extranuclear localization (Table 4). The
above findings suggest that estrogen may exert important
effects on the growth and progression of PTC mainly
through genomic actions mediated by ERα and ERβ1
localized to the nucleus.
Discussion
Both nuclear and extranuclear pools of ERα and ERβ
have been identified [25]. The presence of ERs is funda-
mental for the direct action of estrogen in a given cell,
which translocates from the cytoplasm into the nucleus











aThe female patients of reproductive age were 18–45 years old. bTotal score was ca
to reflect the expression level, which is given as mean ± standard deviation (S.D.). P
nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, excluexist as a cytoplasmic pool tethered to the inner face of
the plasma membrane bilayer through binding to pro-
teins, such as caveolin-1 [25]. The importance of the
subcellular localization of ERα/ERβ1 has been identified
in a variety of cancers. Esophageal cancer invading
through the esophageal wall was found to have a higher
percentage of cells with cytoplasmic expression of ERβ1
than that only limited to the wall [26]. Furthermore, nu-
clear ERβ1 expression was associated with a favorable
response to endocrine therapy in a cohort of 123 familial
breast carcinomas [27]. ERα and ERβ distinctly regulate
gene transcription among many cellular processes. ERα
is well characterized as a mediator of cell proliferation,
especially in breast cancer cells, driving cell proliferation
in the presence of estrogen. ERβ includes five full-lengthtissues from female patients of reproductive agea
PTC (n = 50) NTG (n = 30) P-value
30/50 (60.0%) 2/30 (6.7%) 0.000
3.44 ± 2.80 0.27 ± 1.05 0.000
22/30 (73.3%) 2/2 (100%) 0.000
6/30 (20.0%) 0
2/30 (6.7%) 0
48/50 (96.0%) 28/30 (93.3%) 0.596
6.36 ± 1.64 7.03 ± 1.85 0.001
7/48 (14.6%) 23/28 (82.1%) 0.000
36/48 (75.0%) 5/28 (17.9%)
5/48 (10.4%) 0
lculated from the sum of the proportion staining score and the intensity score
TC, papillary thyroid cancer; NTG, nodular thyroid goiter; Nu, exclusively
sively cytoplasmic staining.
Table 2 ERα/ERβ1 expression patterns in female PTC patients of reproductive age and of advanced reproductive agea
Reproductive age (n = 50) Advanced reproductive age (n = 39) P-value
ERα Positive percentage 30/50 (60.0%) 18/39 (46.2%) 0.194
Total scoreb 3.44 ± 2.80 2.92 ± 3.35 0.342
Subcellular localization Nu 22/30 (73.3%) 7/18 (38.9%) 0.011
Nu + Cyto 6/30 (20.0%) 3/18 (16.7%)
Cyto 2/30 (6.7%) 8/18 (44.4%)
ERβ1 Positive percentage 48/50 (96.0%) 39/39 (100%) 0.206
Total score 6.36 ± 1.64 6.69 ± 1.10 0.391
Subcellular localization Nu 7/48 (14.6%) 3/39 (7.7%) 0.404
Nu + Cyto 36/48 (75.0%) 30/39 (76.9%)
Cyto 5/48 (10.4%) 6/39 (15.4%)
aThe female patients of reproductive age were 18–45 years old, while those of advanced reproductive age were all above 45 years old. bTotal score was calculated
from the sum of proportion staining score and intensity score to reflect the expression level, which is given as mean ± standard deviation (S.D.). PTC, papillary
thyroid cancer; Nu, exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining.
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of the last coding exon. ERβ1 (the wild-type ERβ) has been
found to exert opposing actions to ERα, and inhibits
ERα-mediated proliferation in many cell types [28]. The
expressions of ER subtypes and their clinical signifi-
cance have been assessed in a wide range of different
tumors, such as carcinomas of the breast and uterus
[29,30]. PubMed searches revealed that approximately
16 studies of ER subtype expression in thyroid cancers
including PTC have been reported since 1996. However,
age, gender or tumor types were previously confounding
factors in their statistical analyses, resulting in inconsistent
findings [8]. There was also a lack of investigation of the
subcellular localization of ER subtypes in these previous
studies [8]. IHC assays with monoclonal antibodies are the
most commonly used methods for establishing receptor
status [8]. In this study, we systemically examined the
expression patterns of ERα/β1 in PTC lesions and NTG
tissues in female patients stratified by age. The cut-off
point for age stratification in this study was selected to
be 45 years, as estrogen levels decline with decreased
ovulation in women above 45 years of age [31], who have
approached or entered menopause [1,32]. Furthermore,Figure 2 Detection of Ki-67, mutant P53 and VEGF expression in PTC
and paraffin-embedded PTC tissue sections were stained with the Elivision™
P53 and VEGF. (A) PTC tissue stained with normal rabbit IgG instead of a sp
Ki-67 staining (nuclear expression, total score 5); (C) PTC tissue with positiv
total score 7); (D) PTC tissue with positive VEGF staining (cytoplasmic expre45 years of age is an important cut-off point for TNM
staging of PTC [33]. Our study has shown that not only
the expression level but also positive percentage of ERα
in female PTC patients of reproductive age was significantly
higher than that of age-matched female NTG patients.
However, ERβ1 expression level in PTC was markedly
decreased, although the positive percentage was similar
between female PTC and NTG patients of reproductive
age. In addition, extranuclear ERβ1 expression was signifi-
cantly more frequent in PTC patients when compared
with that of the NTG group. These findings indicate that
ERα overexpression may stimulate the development of
PTC whereas the constitutive expression of ERβ1 may
play a suppressive role through its nuclear actions. Di
Vito M et al. reported ERα overexpression in fine-needle
aspiration biopsy-derived PTC specimens and cells using
laser-capture microdissection followed by real-time quan-
titative PCR and western blotting [11]. Moreover, BCPAP
cell line and cancer stem cells derived from PTC, which
were analyzed under hypoxic conditions, showed a
hypoxia-driven increase in ERα expression [11]. Inoue
and colleagues also found that although PTC cells had
low levels of ERα, following physiological estrogenlesions by immunohistochemical staining (400×). Formalin-fixed
plus two-step system and specific antibodies against Ki-67, mutant
ecific primary antibody (negative control); (B) PTC tissue with positive
e mutant P53 staining (combined nuclear and cytoplasmic expression,
ssion, total score 7).
Table 3 Associations between the subcellular localization of ERα/ERβ1 and clinicopathological factors in female
PTC patients
ERα Tumor size LNM ETE TNM
≤20 mm >20 mm + - + - I/II III/IV
Reproductive agea
Nu (n = 28) 16/28 (57.1%) 12/28 (42.9%) 15/28 (53.6%) 13/28 (46.4%) 10/28 (35.7%) 18/28 (64.3%) 25/28 (89.3%) 3/28 (10.7%)
Nu + Cyto/Cyto (n = 8) 3/8 (37.5%) 5/8 (62.5%) 4/8 (50.0%) 4/8 (50.0%) 0 8/8 (100%) 8/8 (100%) 0
P-value 0.908 0.858 0.047 0.334
Advanced reproductive ageb
Nu (n = 7) 5/7 (71.4%) 2/7 (28.6%) 2/7 (28.6%) 5/7 (71.4%) 4/7 (57.1%) 3/7 (42.9%) 4/7 (57.1%) 3/7 (42.9%)
Nu + Cyto/Cyto (n = 11) 4/11 (36.4%) 7/11 (63.6%) 5/11 (45.5%) 6/11 (54.5%) 2/11 (18.2%) 9/11 (81.8%) 6/11 (54.5%) 5/11 (45.5%)
P-value 0.109 0.474 0.087 0.914
ERβ1 Tumor size LNM ETE TNM
≤20 mm >20 mm + - + - I/II III/IV
Reproductive age
Nu (n = 7) 5/7 (71.4%) 2/7 (28.6%) 2/7 (28.6%) 5/7 (71.4%) 1/7 (14.3%) 6/7 (85.7%) 7/7 (100%) 0
Nu + Cyto/Cyto (n = 41) 19/41 (46.3%) 22/41 (53.7%) 25/41 (61.0%) 16/41 (39.0%) 15/41 (36.6%) 26/41 (63.4%) 38/41 (92.7%) 3/41 (7.3%)
P-value 0.374 0.110 0.247 0.460
Advanced reproductive age
Nu (n = 3) 2/3 (66.7%) 1/3 (33.3%) 0 3/3 (100%) 0 3/3 (100%) 3/3 (100%) 0
Nu + Cyto/Cyto(n = 36) 14/36 (38.9%) 22/36 (61.1%) 16/36 (44.4%) 20/36 (55.5%) 16/36 (44.4%) 20/36 (55.5%) 16/36 (44.4%) 20/36 (55.5%)
P-value 0.300 0.133 0.133 0.064
aThe female patients of reproductive age were 18–45 years old. bThose of advanced reproductive age were all above 45 years old. PTC, papillary thyroid cancer;
Nu, exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining; LNM, lymph node metastasis; ETE,
extrathyroidal extension; TNM: tumor, node and metastasis staging system.
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lated and cell proliferation was promoted [34]. Vannucchi
and colleagues retrospectively followed 123 patients with
differentiated thyroid cancer at different intervals during
pregnancy. They found that patients with thyroid cancer
detected during pregnancy were more likely to develop
persistent and recurrent disease, and up to 87.5% of those
patients had an ERα-positive tumor [35]. These findings
also suggest that ERα may mediate the cancer-promoting
effect of estrogen in PTC patients, and thus can be used as
a marker of malignancy. The increase in the expression of
ERα rather than ERβ in PTC cells induced by estrogen
may be an important mechanism by which estrogen
influences the development of the tumor [36]. Recently,
ERβ has been reported to exhibit significantly higher
expression in follicular thyroid adenoma than in follicular
thyroid cancer (FTC), and to be a stronger differential
diagnostic marker than Ki-67 [37]. Low ERβ expression
appears to be correlated with poor survival in FTC
[37]. In another study, compared with normal thyroid
parenchyma, tumors gained ERα expression and lost
that of ERβ [38]. Postsurgical serum thyroglobulin was
higher in the ERα-positive tumors than the ERα-negative
tumors, and ERβ-negative tumors showed more frequent
vascular invasion than the ERβ-positive tumors [38]. Their
study also suggests that ERβ may mediate inhibitoryactions on the growth and progression of PTC, although
its splice variants were not independently examined [38].
Our previous preliminary study showed that the expres-
sion patterns of ERβ1 and ERβ2 differed between PTC
lesions and NTG tissue, and suggested that different
ERβ splice variants may have differential roles in the
pathogenesis of PTC [39]. Thus, the respective effects
of the two ER subtypes and their splice variants on the
development of PTC need to be separately investigated
and analyzed to provide a basis for the use of corre-
sponding ER agonists or antagonists in therapeutic and
preventive approaches to PTC.
Although epidemiological and experimental studies have
suggested a potential relationship between the develop-
ment of thyroid malignancies and estrogens/ERs, their
precise contributions in the initiation and progression of
PTC have not been well understood [4]. In this study, we
further analyzed the relationships of the two ER subtype
expression patterns with some important clinicopathologi-
cal factors and biological markers in female PTC patients
of reproductive age and advanced reproductive age. Re-
cently, some studies have focused on IHC markers and
evaluated the expression of thyroid transcription factor-1,
Ki-67, P63,P53 and VEGF in PTC lesions [40-42]. These
proteins have been considered as useful markers reflecting
the biological behavior and prognosis of PTC. In this
Table 4 Associations between subcellular localization of ERα/ERβ1 and biological markers in female PTC patients
ERα Ki-67 Mutant P53 VEGF
Reproductive agea
Subcellular localization Positive percentage Total scorec Positive percentage Total score Positive percentage Total score
Nu (n = 28) 27/28 (96.4%) 4.04 ± 1.07 21/28 (75.0%) 4.75 ± 2.98 26/28 (92.9%) 5.93 ± 2.14
Nu + Cyto/Cyto (n = 8) 8/8 (100%) 4.13 ± 0.64 5/8 (62.5%) 3.88 ± 3.36 8/8 (100%) 5.88 ± 1.81
P-value 0.588 0.983 0.486 0.562 0.437 0.683
Advanced reproductive ageb
Nu (n = 7) 6/7 (85.7%) 3.43 ± 1.51 4/7 (57.1%) 3.71 ± 3.50 3/7 (42.9%) 2.29 ± 3.09
Nu + Cyto/Cyto (n = 11) 8/11 (72.7%) 3.55 ± 2.30 8/11 (72.7%) 5.18 ± 3.37 8/11 (72.7%) 4.09 ± 3.05
P-value 0.518 0.121 0.494 0.182 0.205 0.205
ERβ1 Ki-67 Mutant P53 VEGF
Reproductive age
Subcellular localization Positive percentage Total score Positive percentage Total score Positive percentage Total score
Nu (n = 7) 6/7 (85.7%) 3.29 ± 1.60 6/7 (85.7%) 6.00 ± 2.77 4/7 (57.1%) 3.29 ± 3.15
Nu + Cyto/Cyto (n = 41) 40/41 (97.6%) 4.00 ± 1.00 28/41 (68.3%) 4.27 ± 3.11 41/41 (100%) 6.32 ± 1.47
P-value 0.147 0.227 0.349 0.118 0.000 0.015
Advanced reproductive age
Nu (n = 3) 2/3 (66.7%) 2.67 ± 2.31 2/3 (66.7%) 4.67 ± 4.04 1/3 (33.3%) 2.33 ± 4.04
Nu + Cyto/Cyto (n = 36) 31/36 (86.1%) 3.81 ± 1.65 22/36 (61.1%) 4.14 ± 3.41 24/36 (66.7%) 3.61 ± 2.98
P-value 0.370 0.199 0.849 0.699 0.248 0.497
aThe female patients of reproductive age were 18–45 years old. bThose of advanced reproductive age were all above 45 years old. cTotal score was calculated
from the sum of proportion staining score and intensity score to reflect the expression level, which is given as mean ± S.D. PTC, papillary thyroid cancer; Nu,
exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining.
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ations between ERα/β1 expression patterns and that of
Ki-67, mutant P53 and VEGF, and explored the roles of
ER subtypes in the development of PTC. Ki-67 is a
commonly used marker of proliferation in tumors and
is universally expressed among proliferating cells and
absent in quiescent cells. Previous studies have indicated
that Ki-67 can predict disease-free survival and cause-
specific survival of PTC patients as a prognostic marker
[18,43], similar to the findings in breast cancer, an
estrogen-related tumor [44]. Müssig et al. performed a
retrospective analysis of 93 patients including 67 with
PTC and 26 with FTC [45]. Ki-67 expression was
significantly associated with tumor staging [45]. In this
study, we found that ERα expression was positively
correlated with that of Ki-67. Moreover, ETE occurred
more frequently in those female PTC patients of repro-
ductive age with exclusively nuclear ERα expression
when compared with those exhibiting extranuclear
localization of ERα. Our findings suggest that increased
nuclear ERα expression may stimulate the growth of
PTC and is associated with adverse clinical outcome.
Several in vitro studies have demonstrated estradiol-
induced proliferation of thyroid cells using the most
commonly used assays, such as bromodeoxyuridine (BrdU)
incorporation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT), 3H-thymidine incorporation,and trypan blue solution [8]. Furthermore, the actions
of ER-subtype specific agonists on thyroid cancer cell
lines have been studied in vitro: propyl-pyrazole-triol
(PPT, ERα-specific) stimulated cell proliferation, while
diarylpropionitrile (DPN, ERβ-specific) had an inhibitory
effect [46]. It has been proposed that ERα and ERβ
may play different roles in the development of thyroid
carcinoma: ERα activation promotes cell proliferation
and growth, while ERβ activation induces apoptosis
and mediates other suppressive actions of estrogen
[8,47]. Wild-type P53 protein is an important tumor
suppressor that can regulate many cellular activities
including cell cycle arrest, apoptosis, and angiogenesis.
It is not only involved in the control of tumorigenesis,
but also extends to other stages of cancer development,
such as tumor invasion and metastasis [21]. Mutant P53
has been noted in a variety of human malignancies, which
loses its suppressive activity and gains specific ‘mutant
functions’ [48]. The dominant oncogenic properties of
mutant P53 have been recognized through its growth-
promoting effects associated with tumor progression.
Wild-type P53 has a short intracellular half-life and is usu-
ally undetectable by IHC, whereas mutant P53 proteins
have a longer half-life, which results in a sufficient increase
in the amount detectable by IHC. Balta et al. reported that
mutant P53 expression in PTC lesion was significantly
increased as compared with that of benign thyroid tissue
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41.2 to 76.0% [40,49]. Mutant P53 has been identified
as a prognostic indicator for survival in PTC [22,23,50].
Significant correlations were reported between P53 pro-
tein expression detected by immunohistochemistry in the
primary tumor of PTC and tumor size, the presence of
lymph node metastasis and the mean number of lymph
node metastases [50]. In addition, it has been suggested
that P53 gene mutations trigger progression from differen-
tiated to anaplastic carcinoma in human thyroid glands
[51]; P53 is particularly hypermutable in thyroid cancer
[52]. Classical P53 function depends on its nuclear
localization, and gene mutation is one of the important
mechanisms by which P53 is sequestered to the cytoplasm
[19,53]. Although most investigators consider nuclear
expression to be an indication of P53 gene mutation,
cytoplasmic accumulation of mutant P53 is actually
present in some tumors, including colorectal cancer,
lung tumors and melanoma [19,20]. In colorectal can-
cer, tumors with P53 accumulation in both the nucleus
and cytoplasm tend to have a higher mutation rate and
more multiple mutations, accompanied by the most
unfavorable outcome [19]. Ardito G et al. reported that
P53 protein detectable by IHC showed a prevailing
cytoplasmic localization including exclusive cytoplasmic
and nuclear/cytoplasmic positivity in PTC lesions [54].
In our study, by IHC staining with mutant P53 specific
primary antibody we found that it was localized to both
the nucleus and cytoplasm of PTC cells. Furthermore,
the expression level of ERβ1 was negatively correlated with
that of mutant P53 in female PTC patients of reproductive
age, indicating that decreased ERβ1 may be associated with
PTC progression. The interactions between mutant P53
and ER have been suggested to play a potential role in
mammary tissue homeostasis and cancer formation. Using
human colon carcinoma HCT116 cells, Menendez et al.
found that ERβ bound to a ligand and acting in cis is
required or can stimulate the function of selected P53
mutants toward at least some half and full site response
elements and also an endogenous gene target [55]. VEGF
is known as an important regulator of pathological neo-
vascularization and is especially involved in tumor growth
and metastasis. High VEGF expression is associated with
tumor aggressiveness (i.e., metastatic involvement and
recurrence) and poor survival of patients with thyroid
carcinomas [24,56]. Tian et al. reported that the frequency
of VEGF expression was higher in PTC tissue as compared
with that of adjacent normal follicular epithelium [57].
Also, its expression was significantly more frequent in
PTC with LNM than without LNM [57]. In this study,
we found that both the positive percentage and total
score of VEGF expression were significantly decreased
in female PTC patients of reproductive age with exclu-
sively nuclear ERβ1 expression as compared with thosewith extranuclear localization of ERβ1, suggesting that
estrogen may suppress VEGF expression through genomic
actions mediated by ERβ1 localized to the nuclei of PTC
cells. It has been reported that a follicular thyroid cancer
cell line, ML-1, secreted more VEGF after estrogen stimu-
lation, likely as a result of ER signaling [9]. In an animal
model of ischemic stroke, ERβ contributed to the re-
duction of vasogenic edema via the inhibition of VEGF
production [58]. ERβ in the nucleus has been found to
attenuate the hypoxic induction of VEGF mRNA by
directly decreasing HIF-1α binding to the VEGF gene
promoter [59]. The reports described above indicated
the potential effects of ERβ1 activation on mutant P53
and VEGF, consistent with our findings. Our study fur-
ther suggests that ERβ1 may mediate some suppressive
actions on the growth, invasion and metastasis of PTC,
as found in esophageal and breast cancers [26,60].
Conclusions
Our current study has demonstrated the differential ex-
pression patterns of ERα and ERβ1 in PTC and NTG.
These findings indicate that the detection of ER subtypes
may help in the differential diagnosis for PTC, and ERα
especially, may be a useful IHC marker. The associations
of ERα/ERβ1 expression with that of Ki-67, mutant P53,
VEGF and ETE found in female PTC patients of repro-
ductive age suggest that estrogen-activated ERα may me-
diate stimulatory effects on the growth and progression
of PTC, whereas ERβ1 exerts some inhibitory actions.
The increased ERα and decreased ERβ1 expression levels
may play important roles in the pathogenesis of PTC
among female patients of reproductive age. These findings
provide further evidence to support the development of
alternative therapeutic and preventive approaches to PTC
with ERα-specific antagonists or ERβ1-specific agonists.
However, we recognize that our cohort was relatively
small and the follow-up period was not very long, and
thus may not fully reveal the association between ERα/
ERβ1 expression and postoperative recurrence in PTC
patients. Long-term prospective observations of PTC
patients under both standard thyroidectomy and stan-
dard postoperative management are required, and will
be initiated in the near future. The results will help to
better illustrate the relationship between ER subtype
expression and the prognosis of PTC patients.
Abbreviations
ER: Estrogen receptor; PTC: Papillary thyroid cancer; NTG: Nodular thyroid
goiter; ETE: Extrathyroidal extension; LNM: Lymph node metastases;
IHC: Immunohistochemical; VEGF: Vascular epithelial growth factor;
PBS: Phosphate buffered saline; DAB: 3,3′-diamino-benzidine; PS: Proportion
staining score; IS: Intensity score; TS: Total score; BrdU: Bromodeoxyuridine;
MTT: 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide;
PPT: Propyl-pyrazole-triol; DPN: Diarylpropionitrile; Nu: Exclusively nuclear
staining; Nu + Cyto: Combined nuclear and cytoplasmic staining; Cyto: Exclusively
cytoplasmic staining; TNM: tumor, node and metastasis staging system.
Huang et al. BMC Cancer 2014, 14:383 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/383Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LJ had the idea for this research and took responsibility for the design of
this work. HYH and DWW made substantial contributions in acquisition of
data, laboratory analyses and data interpretation and performed all statistical
analyses. LJ, HYH and DWW wrote the manuscript. ZH, SZY and TWP were
involved in revising the manuscript and have given final approval of the
version to be published. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by the Key Scientific and Technological Project
from Liaoning Province (JH2) (No: 2008225007), Program for Liaoning
Excellent Talents in University (LNET) (No: LJQ 2011080), and the Specialized
Research Fund for the Doctoral Program of Higher Education (No:
20122104110006). We thank Edanz Group China for improving the English
language of this manuscript.
Author details
1Department of Endocrinology and Metabolism, Institute of Endocrinology,
The First Affiliated Hospital, China Medical University, Liaoning Provincial Key
Laboratory of Endocrine Diseases, Shenyang 110001, P. R. China.
2Department of General Surgery, The First Affiliated Hospital, China Medical
University, Shenyang 110001, P.R. China.
Received: 29 April 2014 Accepted: 26 May 2014
Published: 29 May 2014
References
1. Rahbari R, Zhang L, Kebebew E: Thyroid cancer gender disparity.
Future Oncol 2010, 6:1771–1779.
2. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role,
molecular bases, and clinical implications. Endocr Rev 2007, 28:742–762.
3. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR,
Anderson WF: Gender is an age-specific effect modifier for papillary cancers
of the thyroid gland. Cancer Epidemiol Biomarkers Prev 2009, 18:1092–1100.
4. Rajoria S, Suriano R, George AL, Shanmugam A, Jussim C, Shin EJ,
Moscatello AL, Geliebter J, Carpi A, Tiwari RK: Estrogen activity as a
preventive and therapeutic target in thyroid cancer. Biomed
Pharmacother 2012, 66:151–158.
5. Brindel P, Doyon F, Rachedi F, Boissin JL, Sebbag J, Shan L, Chungue V, Sun LY,
Bost-Bezeaud F, Petitdidier P, Paoaafaite J, Teuri J, de Vathaire F: Menstrual and
reproductive factors in the risk of differentiated thyroid carcinoma in native
women in French Polynesia: a population-based case–control study. Am J
Epidemiol 2008, 167:219–229.
6. Renoir JM, Marsaud V, Lazennec G: Estrogen receptor signaling as a target for
novel breast cancer therapeutics. Biochem Pharmacol 2013, 85:449–465.
7. Koos RD: Minireview: Putting physiology back into estrogens’ mechanism
of action. Endocrinology 2011, 152:4481–4488.
8. Santin AP, Furlanetto TW: Role of estrogen in thyroid function and
growth regulation. J Thyroid Res 2011, 2011:875125.
9. Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U,
Prakash PB, Tiwari R, Schantz S: Estrogen-mediated angiogenesis in
thyroid tumor microenvironment is mediated through VEGF signaling
pathways. Arch Otolaryngol Head Neck Surg 2011, 137:1146–1153.
10. Dong W, Zhang H, Li J, Guan H, He L, Wang Z, Shan Z, Teng W: Estrogen
Induces Metastatic Potential of Papillary Thyroid Cancer Cells through
Estrogen Receptor alpha and beta. Int J Endocrinol 2013, 2013:941568.
11. di Vito M, de Santis E, Perrone GA, Mari E, Giordano MC, de Antoni E,
Coppola L, Fadda G, Tafani M, Carpi A, Russo MA: Overexpression of
estrogen receptor-alpha in human papillary thyroid carcinomas studied
by laser- capture microdissection and molecular biology. Cancer Sci 2011,
102:1921–1927.
12. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL: A high-throughput proteomic
approach provides distinct signatures for thyroid cancer behavior.
Clin Cancer Res 2011, 17:2385–2394.
13. Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V:
Immunohistochemical study of oestrogen receptors in 351 human
thyroid glands. Singapore Med J 2007, 48:744–747.14. Mete O, Rotstein L, Asa SL: Controversies in thyroid pathology: thyroid
capsule invasion and extrathyroidal extension. Ann Surg Oncol 2010,
17:386–391.
15. Kanehira K, Hu J, Pier T, Sebree L, Huang W: High endogenous avidin binding
activity: an inexpensive and readily available marker for the differential
diagnosis of kidney neoplasms. Int J Clin Exp Pathol 2008, 1:435–439.
16. Lian Y, Li J, Huang Y, Dong W, Shan Z, Teng W, Zhang H: Endogenous
avidin-binding activity in papillary thyroid carcinoma and nodular goiter
tissues and its clinical significance. Endocrine 2012, 32:466–468.
17. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive
factors in breast cancer by immunohistochemical analysis. Mod Pathol
1998, 11:155–168.
18. Ranjbari N, Rahim F: The Ki-67/MIB-1 index level and recurrence of papillary
thyroid carcinoma. Med Hypotheses 2013, 80:311–314.
19. Jansson A, Gentile M, Sun XF: p53 Mutations are present in colorectal
cancer with cytoplasmic p53 accumulation. Int J Cancer 2001, 92:338–341.
20. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL: Expression of mutant
p53 in melanoma. Cancer Res 1991, 51:5976–5979.
21. Roger L, Gadea G, Roux P: Control of cell migration: a tumour suppressor
function for p53? Biol Cell 2006, 98:141–152.
22. Balta AZ, Filiz AI, Kurt Y, Sucullu I, Yucel E, Akin ML: Prognostic value of
oncoprotein expressions in thyroid papillary carcinoma. Med Oncol 2012,
29:734–741.
23. Bachmann K, Pawliska D, Kaifi J, Schurr P, Zorb J, Mann O, Kahl HJ, Izbicki JR,
Strate T: P53 is an independent prognostic factor for survival in thyroid
cancer. Anticancer Res 2007, 27:3993–3997.
24. Salajegheh A, Pakneshan S, Rahman A, Dolan-Evans E, Zhang S, Kwong E,
Gopalan V, Lo CY, Smith RA, Lam AK: Co-regulatory potential of vascular
endothelial growth factor-A and vascular endothelial growth factor-C in
thyroid carcinoma. Hum Pathol 2013, 44:2204–2212.
25. Levin ER: Integration of the extranuclear and nuclear actions of estrogen.
Mol Endocrinol 2005, 19:1951–1959.
26. Liu L, Chirala M, Younes M: Expression of estrogen receptor-beta isoforms
in Barrett’s metaplasia, dysplasia and esophageal adenocarcinoma.
Anticancer Res 2004, 24:2919–2924.
27. Yan M, Rayoo M, Takano EA, Fox SB: Nuclear and cytoplasmic expressions of
ERbeta1 and ERbeta2 are predictive of response to therapy and alters
prognosis in familial breast cancers. Breast Cancer Res Treat 2011, 126:395–405.
28. Shanle EK, Xu W: Selectively targeting estrogen receptors for cancer
treatment. Adv Drug Deliv Rev 2010, 62:1265–1276.
29. Bozkurt KK, Kapucuoglu N: Investigation of immunohistochemical
ERalpha, ERbeta and ERbetacx expressions in normal and neoplastic
breast tissues. Pathol Res Pract 2012, 208:133–139.
30. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA,
Jabbour HN, Saunders PT: Expression of oestrogen receptors, ERalpha,
ERbeta, and ERbeta variants, in endometrial cancers and evidence that
prostaglandin F may play a role in regulating expression of ERalpha.
BMC Cancer 2009, 9:330.
31. Heffner LJ: Advanced maternal age–how old is too old? N Engl J Med
2004, 351:1927–1929.
32. Belchetz PE: Hormonal treatment of postmenopausal women. N Engl J
Med 1994, 330:1062–1071.
33. Edge SB, Compton CC: The American Joint Committee on Cancer:
the 7th edition of the AJCC cancer staging manual and the future
of TNM. Ann Surg Oncol 2010, 17:1471–1474.
34. Inoue H, Oshimo K, Miki H, Kawano M, Monden Y: Immunohistochemical
study of estrogen receptors and the responsiveness to estrogen in
papillary thyroid carcinoma. Cancer 1993, 72:1364–1368.
35. Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz
P, Fugazzola L: Clinical and molecular features of differentiated thyroid
cancer diagnosed during pregnancy. Eur J Endocrinol 2010, 162:145–151.
36. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C: The contributions of
oestrogen receptor isoforms to the development of papillary and
anaplastic thyroid carcinomas. J Pathol 2008, 214:425–433.
37. Heikkila A, Hagstrom J, Maenpaa H, Louhimo J, Siironen P, Heiskanen I,
Haglund C, Arola J: Loss of estrogen receptor Beta expression in follicular
thyroid carcinoma predicts poor outcome. Thyroid 2013, 23:456–465.
38. Magri F, Capelli V, Rotondi M, Leporati P, La Manna L, Ruggiero R, Malovini A,
Bellazzi R, Villani L, Chiovato L: Expression of estrogen and androgen
receptors in differentiated thyroid cancer: an additional criterion to assess
the patient’s risk. Endocr Relat Cancer 2012, 19:463–471.
Huang et al. BMC Cancer 2014, 14:383 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/38339. Dong W, Li J, Huang Y, Zhang H, Shan Z, Teng W: Differential expression
patterns of estrogen receptor (ER)-beta splice variants between papillary
thyroid cancer and nodular thyroid goiter. Med Sci Monit 2012,
18:BR351–BR355.
40. Tan A, Etit D, Bayol U, Altinel D, Tan S: Comparison of proliferating cell nuclear
antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular
weight cytokeratin expressions in papillary thyroid carcinoma, follicular
carcinoma, and follicular adenoma. Ann Diagn Pathol 2011, 15:108–116.
41. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S,
Carcangiu ML: Downregulation of p27KIP1 and Ki67/Mib1 labeling
index support the classification of thyroid carcinoma into prognostically
relevant categories. Am J Surg Pathol 1999, 23:678–685.
42. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV:
Papillary thyroid carcinoma with prominent hobnail features: a new
aggressive variant of moderately differentiated papillary carcinoma.
A clinicopathologic, immunohistochemical, and molecular study of eight
cases. Am J Surg Pathol 2010, 34:44–52.
43. Ito Y, Miyauchi A: Prognostic factors of papillary and follicular carcinomas
in Japan based on data of kuma hospital. J Thyroid Res 2012, 2012:973497.
44. Sheri A, Dowsett M: Developments in Ki67 and other biomarkers for
treatment decision making in breast cancer. Ann Oncol 2012,
23(Suppl 10):x219–x227.
45. Mussig K, Wehrmann T, Dittmann H, Wehrmann M, Ueberberg B, Schulz S,
Bares R, Petersenn S: Expression of the proliferation marker Ki-67 associates
with tumour staging and clinical outcome in differentiated thyroid
carcinomas. Clin Endocrinol (Oxf) 2012, 77:139–145.
46. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA: Oestrogen mediates the
growth of human thyroid carcinoma cells via an oestrogen receptor-ERK
pathway. Cell Prolif 2007, 40:921–935.
47. Chen GG, Vlantis AC, Zeng Q, van Hasselt CA: Regulation of cell growth by
estrogen signaling and potential targets in thyroid cancer. Curr Cancer
Drug Targets 2008, 8:367–377.
48. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P: Understanding
wild-type and mutant p53 activities in human cancer: new landmarks on
the way to targeted therapies. Cancer Gene Ther 2011, 18:2–11.
49. Koo JS, Shin E, Hong SW: Immunohistochemical characteristics of diffuse
sclerosing variant of papillary carcinoma: comparison with conventional
papillary carcinoma. APMIS 2010, 118:744–752.
50. Morita N, Ikeda Y, Takami H: Clinical significance of p53 protein expression in
papillary thyroid carcinoma. World J Surg 2008, 32:2617–2622.
51. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L,
Toussaint B, Klein M, Vignaud JM, Bressenot A: BRAF, p53 and SOX2 in
anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Pathology 2011, 43:447–452.
52. Farid NR: P53 mutations in thyroid carcinoma: tidings from an old foe.
J Endocrinol Invest 2001, 24:536–545.
53. O’Brate A, Giannakakou P: The importance of p53 location: nuclear or
cytoplasmic zip code? Drug Resist Updat 2003, 6:313–322.
54. Ardito G, Revelli L, Boninsegna A, Sgambato A, Moschella F, Marzola MC,
Giustozzi E, Avenia N, Castelli M, Rubello D: Immunohistochemical
evaluation of inflammatory and proliferative markers in adjacent normal
thyroid tissue in patients undergoing total thyroidectomy: results of a
preliminary study. J Exp Clin Cancer Res 2010, 29:77.
55. Menendez D, Inga A, Resnick MA: Estrogen receptor acting in cis enhances
WT and mutant p53 transactivation at canonical and noncanonical p53
target sequences. Proc Natl Acad Sci U S A 2010, 107:1500–1505.
56. Erdem H, Gundogdu C, Sipal S: Correlation of E-cadherin, VEGF, COX-2
expression to prognostic parameters in papillary thyroid carcinoma.
Exp Mol Pathol 2011, 90:312–317.
57. Tian X, Cong M, Zhou W, Zhu J, Liu Q: Relationship between protein
expression of VEGF-C, MMP-2 and lymph node metastasis in papillary
thyroid cancer. J Int Med Res 2008, 36:699–703.
58. Shin JA, Yang SJ, Jeong SI, Park HJ, Choi YH, Park EM: Activation of
estrogen receptor beta reduces blood–brain barrier breakdown
following ischemic injury. Neuroscience 2013, 235:165–173.59. Lim W, Park Y, Cho J, Park C, Park J, Park YK, Park H, Lee Y: Estrogen receptor
beta inhibits transcriptional activity of hypoxia inducible factor-1 through
the downregulation of arylhydrocarbon receptor nuclear translocator.
Breast Cancer Res 2011, 13:R32.
60. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M,
Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JA: ERbeta1
represses basal breast cancer epithelial to mesenchymal transition by
destabilizing EGFR. Breast Cancer Res 2012, 14:R148.
doi:10.1186/1471-2407-14-383
Cite this article as: Huang et al.: Differential expression patterns and
clinical significance of estrogen receptor-α and β in papillary thyroid
carcinoma. BMC Cancer 2014 14:383.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
